Insights: Publications 5 Key Takeaways | Navigating the New U.S. Horizon: Managing Regulatory Friction and De-Risking with Strategic IP
On June 21, 2026, at BIOCHINA Global Forum, Kilpatrick partners Yifan Mao and Gunjan Talati presented a joint briefing addressing what Chinese biopharmaceutical companies must know to operate successfully within an increasingly complex U.S. macro-regulatory and intellectual property landscape. The forum, which was held in San Diego, gathered 400 international participants and industry leaders, bridging the entire industry chain of Chinese biopharmaceutical innovators with global partners from the US, Europe, and emerging markets.
Gunjan and Yifan emphasized that as national security policies increasingly intersect with commercial life sciences, cross-border executives must learn to balance regulatory compliance hurdles with aggressive, sophisticated asset-protection strategies.
The core strategic takeaways include:
- Conduct exhaustive CFIUS, trade policy, and tariff due diligence prior to finalized deal structuring.
- Proactively coordinate international legal, trade compliance, regulatory, and government affairs business units.
- Build a standardized internal compliance framework and actively train deal teams on shifting U.S. regulatory boundaries.
- Deploy structured, phase-gated FTO methodologies early in the development lifecycle to insulate against infringement liabilities.
- Focus heavily on generating litigation-hardened, high-quality U.S. patent claims to maximize asset valuations during corporate exits.
For more information, please contact:
Yifan Mao, ymao@ktslaw.com
Gunjan Talati, gtalati@ktslaw.com
Related People
Disclaimer
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.
